Abstract
The current review will focus on the recent patents for AMPA receptor antagonists and their claims, evidence for their therapeutic effectiveness in the treatment of epilepsy and their potential role in psychiatric and neurodegenerative disorders. It will also highlight the proposed mechanisms of action and the implications thereof for our current understanding of the biomolecular basis of these pathologies. It will conclude with a summary of what we know, but also point out the remaining uncertainties, especially as this relates to the claims in the patent under discussion.
Keywords: AMPA, glutamate, antagonist, epilepsy, schizophrenia, ALS, multiple sclerosis, neuroprotection, anxiety, antiproliferative
2